ATE349218T1 - Methode zur behandlung von schizophrenie - Google Patents

Methode zur behandlung von schizophrenie

Info

Publication number
ATE349218T1
ATE349218T1 AT00918222T AT00918222T ATE349218T1 AT E349218 T1 ATE349218 T1 AT E349218T1 AT 00918222 T AT00918222 T AT 00918222T AT 00918222 T AT00918222 T AT 00918222T AT E349218 T1 ATE349218 T1 AT E349218T1
Authority
AT
Austria
Prior art keywords
cells
therapeutic cells
schizophrenia
eps
negative symptoms
Prior art date
Application number
AT00918222T
Other languages
English (en)
Inventor
Richard C Allen
Michael Cornfeldt
Original Assignee
Titan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Titan Pharmaceuticals Inc filed Critical Titan Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE349218T1 publication Critical patent/ATE349218T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Telephonic Communication Services (AREA)
  • Discharging, Photosensitive Material Shape In Electrophotography (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
AT00918222T 1999-04-09 2000-03-20 Methode zur behandlung von schizophrenie ATE349218T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/289,576 US7115256B1 (en) 1999-04-09 1999-04-09 Methods of treating schizophrenia

Publications (1)

Publication Number Publication Date
ATE349218T1 true ATE349218T1 (de) 2007-01-15

Family

ID=23112130

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00918222T ATE349218T1 (de) 1999-04-09 2000-03-20 Methode zur behandlung von schizophrenie

Country Status (18)

Country Link
US (2) US7115256B1 (de)
EP (1) EP1165100B1 (de)
JP (1) JP2003532621A (de)
AT (1) ATE349218T1 (de)
AU (1) AU778494B2 (de)
CA (1) CA2369439A1 (de)
CY (1) CY1106371T1 (de)
DE (1) DE60032590T2 (de)
DK (1) DK1165100T3 (de)
ES (1) ES2275501T3 (de)
HK (1) HK1040054B (de)
IL (3) IL145815A0 (de)
MX (1) MXPA01010131A (de)
NO (1) NO20014890L (de)
NZ (1) NZ514652A (de)
PT (1) PT1165100E (de)
WO (1) WO2000061156A2 (de)
ZA (1) ZA200108251B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115256B1 (en) * 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
EP1642586A4 (de) * 2003-06-06 2009-06-17 Kringle Pharma Inc Zellhaltige zubereitungen
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
US7940978B2 (en) * 2007-06-05 2011-05-10 General Electric Company Automatic characterization of cellular motion
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
US20100060713A1 (en) * 2008-09-10 2010-03-11 Eastman Kodak Company System and Method for Enhancing Noverbal Aspects of Communication
KR20120007139A (ko) * 2010-07-14 2012-01-20 주식회사 파미니티 탄소나노튜브를 유효성분으로 함유하는 뇌질환 예방 또는 치료용 조성물
WO2014128882A1 (ja) * 2013-02-21 2014-08-28 医療法人 和楽会 不安うつ病の治療薬
US11690876B2 (en) 2017-05-10 2023-07-04 University Of Rochester Methods of treating neuropsychiatric disorders
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
EP3803866A4 (de) 2018-05-24 2022-03-16 Nureva Inc. Verfahren, vorrichtung und computerlesbare medien zur verwaltung halbkonstanter (persistenter) schallquellen in mikrofonaufnahme-/-fokuszonen
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE464816B (sv) 1985-10-15 1991-06-17 Nilsson Kjell Makroporoesa partiklar, foerfarande foer dess framstaellning och dess anvaendning
US5650148A (en) 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
US5447948A (en) 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
DK0755258T3 (da) 1994-04-13 2002-05-13 Res Corp Technologies Inc Fremgangsmåde til behandling af sygdom ved at anvende Sertoli-celler og allo-transplantater eller xeno-transplantater
AU7963998A (en) 1997-06-13 1998-12-30 University Technology Corporation Transplantation of immortalized dopamine cells to improve neurological deficits
EP1044024A1 (de) 1998-01-02 2000-10-18 Titan Pharmaceuticals, Inc. Verwendung pigmentierter retinaler epithelzellen zur schaffung eines immunpriviligierten ortes
US7115256B1 (en) * 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia

Also Published As

Publication number Publication date
IL177538A0 (en) 2006-12-10
EP1165100B1 (de) 2006-12-27
CA2369439A1 (en) 2000-10-19
IL145815A (en) 2008-12-29
NO20014890D0 (no) 2001-10-08
ES2275501T3 (es) 2007-06-16
JP2003532621A (ja) 2003-11-05
WO2000061156A2 (en) 2000-10-19
PT1165100E (pt) 2007-02-28
US7115256B1 (en) 2006-10-03
AU3907100A (en) 2000-11-14
NZ514652A (en) 2004-06-25
CY1106371T1 (el) 2011-10-12
HK1040054A1 (en) 2002-05-24
DK1165100T3 (da) 2007-05-07
IL145815A0 (en) 2002-07-25
AU778494B2 (en) 2004-12-09
MXPA01010131A (es) 2002-08-20
DE60032590T2 (de) 2007-10-11
EP1165100A2 (de) 2002-01-02
HK1040054B (en) 2007-08-10
NO20014890L (no) 2001-12-05
WO2000061156A3 (en) 2001-01-25
DE60032590D1 (de) 2007-02-08
ZA200108251B (en) 2002-12-24
US20060292128A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
DE60032590D1 (de) Methode zur behandlung von schizophrenie
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DK0721449T3 (da) Inhibitorer af beta-amyloidproteinproduktion
TW200510306A (en) Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
EP2465923A3 (de) Verfahren zur Verwendung von Zellen aus Fettgewebe zur Behandlung kardiovaskulärer Erkrankungen
PH12022551105A1 (en) Tyk2 pseudokinase ligands
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
ATE385807T1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
PH12021553102A1 (en) Methods of treating fabry disease in patients having renal impairment
BR112021022380A2 (pt) Inibidores de jak
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE60028538D1 (de) Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
BR112022005608A2 (pt) Inibidores de jak
MA27607A1 (fr) Peptides cyto-modulateurs pour traiter la cystite interstitielle
DE60009315D1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
BR112022002390A2 (pt) Inibidores de jak
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DK1778834T3 (da) Fremgangsmåder til anvendelse af regenerative celler i behandlingen af renale sygdomme og lidelser
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
DE602004015321D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
UA92908C2 (ru) Соединения, производные от 5-тиоксилозы, и их терапевтическое применение
ATE535246T1 (de) Zusammensetzung zur behandlung von erkrankungen des zentralen nervensystems

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1165100

Country of ref document: EP

REN Ceased due to non-payment of the annual fee